WARNING LETTER
Medline Industries, LP
MARCS-CMS 723866 —
March 25, 2026
Delivery Method:
VIA Electronic Mail
Product:
Medical Devices
Recipient:
Recipient Name
Jim Boyle
Recipient Title
CEO
Medline Industries, LP
3 Lakes Drive
Northfield
,
IL
60093
United States
JBoyle@medline.com
Issuing Office:
Center for Devices and Radiological Health
United States
WARNING LETTER
CMS # 723866
March 25, 2026
Dear Mr. Boyle:
During an inspection of your firm, Medline Industries, LP (NAMIC Division), located at 10 Glens Falls Tech Park, Glen Falls, NY 12801, from December 1, 2025 through December 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and assembles numerous medical devices into Cardiovascular Procedure Kits to include (but not limited to) NAMIC brand Angiographic Control Syringes and manifolds intended to be used for the intra-arterial or intravenous administration of radiographic contrast media. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.
Quality System Regulation Violations
This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21,
Code of Federal Regulations
(CFR), Part 820.
We received a response from Mr. Richard Kalita, Senior Manager of Quality Assurance, dated January 13, 2026, and February 27, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:
1. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).
Specifically:
A. Your firm failed to implement section 5.8.4 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 40), which states “***
[the] degree of corrective and preventive action taken to eliminate or minimize actual or potential nonconformities must be appropriate to the magnitude of the problem and commensurate with the risks encountered
***”, in that your firm did not take actions commensurate with risk for NAMIC Angiographic Control Syringes in the field for which CAPA-01872 was opened due to an increase in complaints in June 2023 regarding disconnection from manifolds you attributed to the presence of excess silicone. Your Health Hazard Evaluation (HHE) Qual-124366 dated June 11, 2024, determined the risk was low, which is inconsistent with your design failure modes and effectiveness analysis (dFMEA) (RA2022047; Rev. 4) which identified "air embolism" as the highest severity issue for loose connections. Your firm’s corrective actions only included scrapping devices in inventory and increasing the cleaning frequency of the
(b)(4)
machine to prevent excess silicone from migrating to the luer connector, despite receiving 221 complaints and filing 177 MDRs for the disconnection of the NAMIC Angiographic Control Syringes from manifolds which impact patients and clinicians, including one (1) MDR # 3015910259-2025-00109 involving the injection of air into a patient (Complaint #
(b)(4)
dated
(b)(4)
) and one (1) MDR # 3015910259-2024-00045 involving biohazard exposure of a clinician (Complaint #
(b)(4)
dated
(b)(4)
).
B. Your firm failed to implement section 5.19 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 47; Effective: 11/1/25), in that “***
while in the effectiveness check stage and either the effectiveness check failed or additional root causes or problems are identified; the CAPA may be routed back to a previous phase or an additional CAPA may be opened at the discretion of the CRB [CAPA Review Board]. Risk and containment activities must be considered when moving the CAPA to a previous phase
***”. Your firm did not execute any of the above actions for CAPA-01872 when trending data revealed, as early as Quarter 1 of 2025, that the complaints per million (CPM) of NAMIC Angiographic Control Syringes manufactured post-corrective action was at 16.90 CPM followed by 16.44 CPM in Quarter 2 and 26.81 CPM in Quarter 3, all of which was above the 15.98 CPM threshold for complaints received for disconnections established in the verification of effectiveness plan (VOE AI#
(b)(4)
to start 1/15/25; Updated 8/1/25). Moreover, the total rate of complaints, including devices manufactured before and after the implementation of the corrective action (starting January 15, 2025) and for product where the manufacturing date is unknown, was 39.95 CPM, 31.62 CPM, and 59.27 CPM for Quarters 1, 2 and 3 of 2025, respectively.
We reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, your firm acknowledged that the corrective action was not effective, closed CAPA-01872, and opened a new CAPA-02612 to further investigate the issue. You also communicate a plan to issue a field correction with a safety notice to all customers who have received or will receive NAMIC Angiographic Control Syringes, based on a HHE (Qual-156459) of post-market data from June 2023 to December 2025, to alert them about the unwinding issue and provide reinforced instructions and additional guidance. You further state that you plan to develop
(b)(4)
syringe solution currently undergoing verification with production targeted to begin in
(b)(4)
and proposed that a field notice rather than a full product removal was appropriate given the effectiveness of prior communications, the upcoming alternative solution, and prevention of a market shortage.
In your latest response on February 27, 2026, you state that you updated your HHE (Qual-156459; Approved 2/26/26) to reflect your revised plan to conduct a removal of NAMIC Angiographic Control Syringes based on multiple discussions with the agency regarding your recall strategy. This HHE reports a total CPM for the syringe/ manifold disconnection issue from June 2023 to February 19, 2026, as 62.62 CPM (250 complaints out of
(b)(4)
syringes manufactured ending
(b)(4)
). On March 13, 2026, an 806 Report was submitted to the agency for the removal of these devices (
(b)(4)
).
You also indicate that you initiated an additional CAPA-02627 under which you conducted a systemic review of all open CAPAs and trained personnel on an updated CAPA procedure (SOP-00022) which requires more frequent post-market data reviews per established guidance. The targeted completion date for CAPA-02627 is June 30, 2026.
With regards to CAPA-02612, no information was provided on when you anticipate a new investigation will be completed to determine the cause(s) of the disconnections between the syringes and manifolds to assure your actions are timely and commensurate with risk of this issue. Furthermore, no assurance was provided that the scope of the product removal will include affected devices manufactured both before and after the corrective action (April 17, 2024) since the corrective action was found to be ineffective. Furthermore, the manufacturing quantities documented in your updated HHE fall short of the nearly
(b)(4)
syringes your Senior Director of Quality stated were manufactured (approximately
(b)(4)
devices from
(b)(4)
to
(b)(4)
and nearly
(b)(4)
devices from
(b)(4)
to
(b)(4)
) in that it states that only
(b)(4)
syringes were manufactured through
(b)(4)
, resulting in 62.62 CPM (250 complaints), without defining the manufacturing start date of affected products. The HHE also incorrectly specifies a corrective action start date of June 2024 instead of April 16, 2024, as specified in CAPA-01872.
With regards to CAPA-02627, you did not identify actions that assure that employees will follow your corrective action procedure to route the CAPA back to a previous phase or open an additional CAPA as soon as it is evident that corrective actions are not effective, as was the case in
(b)(4)
of 2025 when your complaint analysis data showed that the CPM for syringe and manifold disconnections was above the established CPM thresholds.
Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and/or corrective actions, including any supporting evidence.
2. Failure to establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1).
Specifically, your firm failed to implement sections 6.2.2 (
(b)(4)
Cleaning) and 6.3 (General Requirements) of your “GN 010 - Manufacturing Cleaning Procedure” (NMC-00228; Rev. 7; Effective: 5/2/25) which state “
a top-to-bottom cleaning of the controlled environments will be conducted, at minimum,
(b)(4)
***The cleaning shall also include all equipment not routinely cleaned by operators***” and “***Always clean the
(b)(4)
first and work toward the
(b)(4)
of cleaning with the
(b)(4)
being last
***,” respectively, of controlled environments such as the clean rooms where you manufacture various Angiographic and Radiology Syringes. In addition, the corresponding forms titled “
(b)(4)
Cleaning Schedule and Sign-off Sheet” form (NMC-00228-F-00001; Rev. 2) and “
(b)(4)
Cleaning Schedule and Sign-off Sheet” (NMC-00228-F-00002; Rev.1) are inadequate because they fail to ensure consistent implementation of sections 6.2.2 and 6.3 of NMC-00228 due to absence of specific instructions requiring the cleaning of top of manufacturing equipment as is included for the cleaning of vents, ceiling lights, walls, benches, cabinets, fixtures, etc. For example, on December 1, 2025, the investigator observed a visible accumulation of particulate on the top of manufacturing equipment in cleanrooms including the
(b)(4)
syringe manufacturing machine (ID # 90303527),
(b)(4)
machine (ID # 90306846),
(b)(4)
manufacturing machine (ID # 90308616), and
(b)(4)
machine (Asset # 8974). There have been approximately 114 complaints regarding foreign matter or hair in the package or device from December 2023 to at least December 1, 2025.
We reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, you state you performed immediate ad-hoc cleaning of all equipment to remove observed particulate matter, established preventative maintenance schedules based on
(b)(4)
of monitoring data, and updated the cleaning and preventative maintenance procedures (NMC-00228 and NMC-00171) to formalize these requirements followed by training under CAPA-02518. Additionally, you state you developed an ad-hoc cleaning procedure (NMC-01120) and addressed air filtration concerns by installing
(b)(4)
indicators around all cleanroom
(b)(4)
vents to ensure proper clearance, repaired damaged vents, and updated your environmental control procedure (NMC-00233) to include inspection and clearance requirements. You also determined that validation of the cleaning process was not required.
In your latest response on February 27, 2026, you state you conducted a comprehensive review of the cleanroom manufacturing environments and identified improvement opportunities but not any risks. The target completion for these additional actions is April 30, 2026, and the target completion date of CAPA-02518 is July 17, 2026.
However, there were no corrective actions identified to assess the impact of products in the field and inventory for products which have been manufactured in these cleanrooms since the last documented cleaning of equipment tops on November 26, 2023, including review of the manufacturing dates of products referenced in the 114 complaints received for foreign matter or hair since this date as a part of the respective complaint investigations. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and/or corrective actions, including any supporting evidence.
3. Failure to establish and maintain procedures for verifying the device design. Design verification shall confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).
Specifically, your firm’s design verification conducted under “Design Verification Protocol Polycarbonate Female Luer ISO 80369-7” (P017333; Rev. B; Approved: 10/7/20) with resulting “Design Verification Report Polycarbonate Female Luer ISO 80369-7” (P017334; Rev. A; Approved: 6/30/20) fails to demonstrate that the polycarbonate female luer connector components of your Fluid Management product lines (e.g., stopcock product family, manifold product family, disposable transducer product family, Y adaptor, etc.), which underwent changes to their threads and taper dimensions to become BS EN ISO 80369-7 compliant, meet the dimensional and functional testing requirements specified in this standard. For example, there was no documentation in the protocol (or elsewhere) on why design verification testing was only performed on a single female luer connector (Part # 24644210) and not any of the other
(b)(4)
connectors listed in the “Scope” section of this protocol which were also impacted by this design change. Moreover, this solely tested connector is not included in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9/7/22) which captures all luer connectors affected by this design change.
We reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026 response, you state you revised the design verification procedure (NMC-00155) to require documentation of part selection rationale, added product configuration tables and guidance for recording representative SKU selection and rationale for selection in the Design Verification Protocol Template (NMC-00155-F-00001), and amended design change file QUAL-66717 to include the missing justification for part selection under CAPA-02610.
In your latest response on February 27, 2026, you state you conducted a comprehensive review of all design changes from
(b)(4)
to present that required design verification testing and uncovered four (4) instances of insufficient documentation of part rationale which will require protocol updates with appropriate justification. The target completion of CAPA-02610 is June 1, 2026.
However, review of the “Unit Rationale” provided revealed that it fails to explain how design verification testing of part number 41338202 covers anything beyond the manifold product family, such as the stopcock product family, disposable transducer product family, and Y adaptor of the Fluid Management product lines which were in the scope of the Design Verification. Moreover, this rationale does not explain why this part number was not listed in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9/7/22) meant to capture all the luer connectors affected by this design change. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and/or corrective actions, including any supporting evidence.
Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.
Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.
On February 2, 2024, the FDA issued a
final rule
amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on December 1, 2025 to December 12, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https://www.fda.gov/medical-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp/quality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.
Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and/or corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and/or corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and/or corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.
Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 723866” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.
Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.
Sincerely,
/S/
Barbara A. Marsden
Director
Office of Regulatory Programs
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
CC: Bradley R. Pratt, Sr. Director of Manufacturing Operations, BPratt@medline.com
Content current as of:
04/07/2026
Regulated Product(s)
Medical Devices